Go back

Broad cancer plan needed to get most out of R&D, say companies


Pharmaceutical industry says Europe must ‘embrace new approaches to research and regulation’

The European Cancer Plan being developed by the European Commission must tackle all aspects of cancer prevention, treatment and care, a senior pharmaceutical industry representative has said.

Europe must “embrace new approaches to clinical research and regulation, healthcare technology assessment and decision-making”, Nathalie Moll, director general of the European Federation of Pharmaceutical Industries and Associations, said in a blog post published on 15 January.

This article is only available to *Research Professional subscribers. If you are a subscriber you can read the article in full on researchprofessional.com